B · Normal
On October 3, biopharmaceutical company Agenus reported that its BOT+BAL combination therapy achieved an estimated three-year survival rate of 48% in patients with recurrent ovarian cancer.
Related telegraphs
On October 10, the U.S. Food and Drug Administration (FDA) approved a drug for t
10-10 00:50
On October 9, India plans to introduce stricter control measures on prescription
10-09 13:44
[AstraZeneca: Datroway approved in China for metastatic triple-negative breast c
10-08 16:49
[Dongguang Pharmaceutical's double insulin degluaspart was approved and became t
10-08 16:46
[China implements medical rehabilitation and nursing capacity expansion and impr
10-08 09:12
[Two departments: strive to achieve about 0.48 rehabilitation nursing beds per 1
10-08 09:03
Comments